Related Experiment Video
Updated: Jul 14, 2026
11:46
Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice
Published on: April 27, 2014
Future pharmacotherapy in chronic bladder hypersensory conditions
Expert Opinion on Emerging Drugs
|July 3, 2007
Summary
Lower urinary tract symptoms (LUTS) affect many adults and are often treated empirically. Future LUTS therapies may target bladder defects and inflammation for more effective patient outcomes.
Area of Science:
- Urology
- Neuroscience
- Pharmacology
Background:
- Lower urinary tract symptoms (LUTS) are prevalent in adults, affecting both genders.
- LUTS are characterized as a chronic hypersensory bladder condition.
- Current LUTS treatment is largely empirical due to limited pathophysiological understanding and measurement tools.
Discussion:
- Future LUTS treatments could target intrinsic bladder defects in the urothelium, smooth muscle, or nerves.
- Pharmacologic agents can be directly delivered to bladder compartments via transurethral catheterization.
- Non-bacterial bladder inflammation and central nervous system (CNS) abnormalities are potential targets for future pharmacotherapy.
Key Insights:
- LUTS represent a significant, widespread health issue.
- Current treatment limitations necessitate novel therapeutic strategies.
- Targeting bladder physiology and CNS factors offers promising avenues for LUTS management.
Outlook:
- Advancements in understanding bladder pathophysiology will drive innovative LUTS treatments.
- Direct drug delivery methods may enhance therapeutic efficacy for bladder conditions.
- Exploring non-bacterial inflammation and CNS contributions to LUTS could reveal new pharmacotherapeutic targets.
Related Concept Videos
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:17Urinary Tract Infection IV: Nursing Management
In managing urinary tract infections (UTIs) in nursing, a comprehensive assessment is essential. Begin by gathering subjective data, such as the patient’s complaints of dysuria (painful urination), urinary frequency, urgency, suprapubic pain, and any lower abdominal discomfort. This information can be complemented by questions regarding previous UTIs, sexual activity, and personal hygiene practices, which can provide insight into risk factors. Objective assessment should focus on signs like...
01:26The Micturition Reflex
Urination, or micturition involves the coordination of the bladder's detrusor muscle and two sphincters to ensure controlled bladder emptying.
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating urine...
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating urine...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...